Safety and feasibility of intravenous fresh adipose-derived mesenchymal stem cells in secondary progressive multiple sclerosis: phase I/IIa clinical results.
- DOI
- 10.1186/s13287-026-04933-6
- Published
- 2026 Feb 22
- Container
- Stem cell research & therapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s13287-026-04933-6,
title = {Safety and feasibility of intravenous fresh adipose-derived mesenchymal stem cells in secondary progressive multiple sclerosis: phase I/IIa clinical results.},
author = {Arab FL and Yousefi F and Naderi-Meshkin H and Mirahmadi M and Faraji F and Nikkhah K and Amiri H and Erfani M and Ayoobi F and Tabasi NS and Nikkhah A and Mahmoudi M},
year = {2026},
journal = {Stem cell research \& therapy},
doi = {10.1186/s13287-026-04933-6},
url = {https://doi.org/10.1186/s13287-026-04933-6}
}RIS
TY - JOUR TI - Safety and feasibility of intravenous fresh adipose-derived mesenchymal stem cells in secondary progressive multiple sclerosis: phase I/IIa clinical results. AU - Arab FL AU - Yousefi F AU - Naderi-Meshkin H AU - Mirahmadi M AU - Faraji F AU - Nikkhah K AU - Amiri H AU - Erfani M AU - Ayoobi F AU - Tabasi NS AU - Nikkhah A AU - Mahmoudi M PY - 2026 JO - Stem cell research & therapy DO - 10.1186/s13287-026-04933-6 UR - https://doi.org/10.1186/s13287-026-04933-6 ER -
APA
FL, A., F, Y., H, N., M, M., F, F., K, N., H, A., M, E., F, A., NS, T., A, N., & M, M. (2026). Safety and feasibility of intravenous fresh adipose-derived mesenchymal stem cells in secondary progressive multiple sclerosis: phase I/IIa clinical results.. Stem cell research & therapy. https://doi.org/10.1186/s13287-026-04933-6
Source records
- pubmed · retrieved 2026-09-26T20:01:17.172Z